Marie-Claude Bourgeois-Daigneault, Ph.D.

Université de Montréal, CRCHUM et Institut du cancer de Montréal
 

2004/09 - 2007/05              B.Sc.; Biology, Microbiology and Immunology

                                                         Université de Montréal

 

2007/09 - 2008/05              M.Sc.; Microbiology and Immunology; Dr. Jacques Thibodeau

                                                         Université de Montréal

                                                         The regulation and presentation of antigens by MHC class II molecules.

 

2008/05 - 2012/11              Ph.D.; Microbiology and Immunology; Dr. Jacques Thibodeau

                                                         Université de Montréal

                                                         Structure-function of MARCH1, an E3 ubiquitin ligase that regulates the presentation of antigens by MHC class II molecules.

 

2013/04 - 2017/11              Post-doctoral studies; Dr. John Bell 

                                                         Ottawa Hospital Research Institute

                                                         University of Ottawa

                                                         Study of the immune facet of cancer treatment with oncolytic viruses with a focus on breast cancer. 

 

2017/11 - 2018/07              Research Associate; Dr. John Bell 

                                                         Ottawa Hospital Research Institute

                                                         University of Ottawa 

                                                         Anti-tumor vaccination techniques using oncolytic viruses. 

2009-2011          Doctoral award; The Cole foundation

2015-2017          Post-doctoral award; Canadian Institutes of Health Research

2018                        Michael W. McBurney post-doctoral prize; University of Ottawa

2018                        Profiled as a model of success for post-doctoral fellows

                                    Faculty of medicine, University of Ottawa

2018                        Selected as one of the 4 most promising young scientists of 2018

                                    Ontario Institute for Cancer Research (OICR) 

2019-2023          Scholar Salary Award – Junior 1; Fonds de recherche santé Québec and Fondation du cancer du sein du Québec

  • 2018-2023           Start-up funds; Institut du cancer de Montréal (250 000 $)

  • 2018-2021           Start-up funds; Centre de recherche du CRCHUM (150 000 $)

  • 2018-2023           Transition funds; Cole Foundation (150 000 $)

  • 2019-2023           Establishment fund for young researchers; Fonds de recherche santé Québec and Fondation du cancer du sein du Québec (80 000 $)

  1. the use of oncolytic viruses as personalized anti-tumor vaccination platforms

  2. the development of heterologous, oncolytic bacteria-oncolytic virus anti-tumor vaccination strategies

  3. the study of the importance of the immunoproteasome for the immunotherapeutic activity of oncolytic viruses.

 

 

PhD students

Victor Mullins-Dansereau (victor.mullins-dansereau@umontreal.ca)

Gregory Petrazzo (gregory.petrazzo@umontreal.ca)

Karen Geoffroy (ka.geoffroy@gmail.com)

 

MSc student

Delphine Béland (delphine.beland@umontreal.ca)

  1. Bourgeois-Daigneault M.C, Roy D.G, Falls T, Twumasi-Boateng K, St-Germain L.E, Marguerie M, Garcia V, Selman M, Jennings V.A, Pettigrew J, Amos S, Diallo J.S, Nelson B and Bell J.C. Oncolytic vesicular stomatitis virus expressing interferon-γhas enhanced therapeutic activityMolecular Therapy-Oncolytics2016.

  2. Falls T, Roy D.G, Bell J.C and Bourgeois-Daigneault M.C. Murine Tumor Models for Oncolytic Rhabdo-VirotherapyILAR Journal2016. *Corresponding author

  3. Bourgeois-Daigneault M.C*, St-Germain L.E, Roy D.G, Pelin A, Aitken A.S, Arulanandam R, Falls T, Garcia V, Diallo J.S and Bell J.C. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatmentBreast Cancer Research2016.

  4. Aitken A, Roy D and Bourgeois-Daigneault M.C. Taking a stab at cancer ; Oncolytic virus-mediated anti-cancer vaccination strategiesBiomedicines 2017.

  5. Aitken A.S, Roy D.G, Martin N.T, Sad S, Bell, J.C and Bourgeois-Daigneault M.C. Brief communication;A heterologous oncolytic bacteria-virus prime-boost approach for anti-cancer vaccination in mice.Journal of Immunotherapy 2018.

  6. Bourgeois-Daigneault M.C, Roy D.G, Aitken A.S, El Sayes N, Martin N.T, Varette O, Falls T, St-Germain L.E, Pelin A, Lichty B.D, Stojdl D.F, Ungerechts G, Diallo J.S. and Bell J.C. Neo-adjuvant oncolytic virotherapy prior to surgery sensitizes triple-negative breast cancer to immune checkpoint therapyScience Translational Medicine 2018.

  7. Martin N.T, Roy D.G, Workenhe S, Wollenberg D.J.M.V.D, Hoeben R.C, Mossman K, Bell J.C and Bourgeois-Daigneault M.C.  Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancerScientific Reports 2019.

  8. Mullins-Dansereau V, Petrazzo G, Geoffroy K, Beland D and Bourgeois-Daigneault M.C. Pre-surgical oncolytic virotherapy improves breast cancer outcomesOncoImmunology,volume 8 epub e1655363, 2019.